# US 2025/0166826 A1 · Rapid assay for detecting mirna: compositions and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0166826 A1
- Document ID: US20250166826A1
- Status: Published application
- Kind: A1
- Application number: 18/949,011
- Filed: 2024-11-15
- Published: 2025-05-22
- Earliest claimed: 2023-11-16
- Assignees: MI:RNA Ltd.
- Applicants: Mi:Rna Ltd.
- Inventors: Eve HANKS; Robert COULTOUS
- Web page: https://patentgrep.com/patent/US20250166826A1

## CPC

- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- C12N 15/1096: {cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR}
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/689: for bacteria
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

An diagnostic assay for rapidly detecting level of expression of mRNA within low volume or low expression samples by proxy of generated cDNA. The method provides for the detection of cDNA of a diseased subject with at least one pre-determined reference level cDNA characteristic of a non-diseased subject wherein a deviation of the level of expression of said cDNA in comparison with the at least one reference level cDNA allows for the diagnosis and/or prognosis of the disease.

## Claims

### Claim 1

A method for detecting the presence of mycobacterial disease in a subject, comprising the steps of:
(a) isolating miRNA molecules within a sample from a subject;
(b) translating the miRNA molecules to cDNA or molecules;
(c) amplifying the cDNA molecules to a detectable concentration;
(d) probing for the cDNA molecules complimentary to the desired miRNA markers;
(e) determining a level of expression of the miRNA molecules within a sample from a subject by the level of cDNA molecules probed for the desired miRNA markers; and
(f) using one or more Artificial Intelligence (AI) model to predict the disease condition of the subject.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the one or more AI model compares the level of expression of each cDNA molecule with at least one pre-determined reference level cDNA molecule characteristic of a non-diseased subject wherein a deviation of the level of expression of said cDNA molecule in comparison with the at least one reference level cDNA molecule allows for the diagnosis and/or prognosis of the disease.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the cDNA molecule may also be a reverse compliment cDNA.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the miRNA molecules are selected from a group consisting of nucleic acid sequence having at least 95%, 97%, 98% or 99% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cDNA molecules are selected from a group consisting of nucleic acid sequence having at least 95%, 97%, 98% or 99% sequence identity to SEQ ID NO:33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, and 88.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the method further comprises the use of at least one normalizer and/or control miRNA or cDNA molecule.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the at least one normalizer miRNA molecule is selected from a group consisting of nucleic acid sequence having at least 95%, 97%, 98% or 99% sequence identity to SEQ ID NO:25, 26, 27, 28 and 29.

### Claim 8 (depends on 6)

The method according to claim 6, wherein the at least one normalizer cDNA molecule is selected from a group consisting of nucleic acid sequence having at least 95%, 97%, 98% or 99% sequence identity to SEQ ID NO:57, 58, 59, 60, 61, 89, 90, 91, 92, and 93.

### Claim 9 (depends on 6)

The method according to claim 6, wherein the at least one of the control miRNA molecules is selected from a group consisting of nucleic acid sequence having at least 95%, 97%, 98% or 99% sequence identity to SEQ ID NO:30, 31, and 32.

### Claim 10 (depends on 6)

The method according to claim 6, wherein the at least one of the control cDNA molecules is selected from a group consisting of nucleic acid sequence having at least 95%, 97%, 98% or 99% sequence identity to SEQ ID NO:62, 63, 64, 94, 95 and 96.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the method further comprises the step of using a machine learning algorithm for predictive modelling.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the method comprises the use of a combination of AI models.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the subject is a mammal.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the subject is a cow, sheep, goat, deer, llama, alpaca or vicuna.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the disease is selected from a group consisting of mycobacterial disease, including but not restricted to Johne's disease, tuberculosis and Crohn's disease, or any other disease caused by Mycobacterium avium subspecies paratuberculosis (MAP) or any other species within the Mycobacterium genus.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the sample is a biofluid selected from the group consisting of blood, urine, milk, tissue fluid, saliva, milk, cerebrospinal fluid (CSF), faeces or another biofluid.

### Claim 17 (depends on 1)

The method according to claim 1, wherein the miRNA molecules are cell free miRNA molecules.

### Claim 18

A method of selecting a panel for use in disease diagnosis comprising the steps of:
(a) selecting a group of miRNA molecules the differential expression of which may be associated with a disease condition;
(b) transcribing the miRNA into cDNA;
(c) determining the levels miRNA based on the cDNA in the sample; and
(d) training one or more AI model to be able to predict the disease condition.

### Claim 19 (depends on 1)

A kit for use in performing the method of the claim 1 comprising means for determining the level of expression of each one of the following miRNA molecules by proxy of the corresponding cDNA: nucleic acid sequence having at least 95%, 97%, 98% or 99% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24.
